Evidence map›Paper›PMID 41576306›Full record

ArticleJCO precision oncology2026

Identification of Predictive Genomic Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis of Real-World Clinicogenomic Data.

Mimma Rizzo, Gaetano Pezzicoli, Camilla Porta, Massimiliano Povero, Lorenzo Pradelli, Emilia Sicari, Valentina Sara Barbiero, Camillo Porta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mimma RizzoDivision of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy.ORCID 0000-0001-7743-741X
Gaetano PezzicoliDivision of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy.
Camilla PortaAdRes HE&OR, Turin, Italy.
Massimiliano PoveroAdRes HE&OR, Turin, Italy.
Lorenzo PradelliAdRes HE&OR, Turin, Italy.ORCID 0000-0002-7648-8917
Emilia SicariRoche S.p.A., Monza, Italy.ORCID 0009-0002-9010-3005
Valentina Sara BarbieroRoche S.p.A., Monza, Italy.
Camillo PortaDivision of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy.ORCID 0000-0003-2412-1563

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLimited validated prognostic biomarkers are available to guide treatment decisions for patients with metastatic clear cell renal cell carcinoma (mccRCC).

methodsThis study used a US-based renal cell cancer clinicogenomic database to analyze the predictive value of genomic alterations in patients treated with immune checkpoint inhibitors (ICI) and antiangiogenic (AA) therapies. Three co-occurring gene clusters (C) were considered: (C1)

resultsIn first line, among 493 patients who underwent systemic therapy, 201 (40.8%) and 172 (34.9%) received AA monotherapy (AAm) and ICI combinations (ICI-C), respectively.

conclusionThese findings require prospective validation to confirm their clinical utility.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsAgedFemaleGenomicsHumansMaleMiddle AgedPrognosisBiomarkers, Tumor

Identifiers

PMID41576306
PMCPMC12834269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.